Inhibition of pathogens by probiotic bacteria

• US 20050232909A1
• Filed: 12/06/2004
• Published: 10/20/2005
• Est. Priority Date: 11/08/1999
• Status: Abandoned Application

• Current Assignee: Farmer SEAN
• Original Assignee: Farmer SEAN
• Inventors: Farmer, Sean
• Application Number:
  US11/005,897
• Publication Number:
  US 20050232909A1
• Time in Patent Office: Days
• US Class Current: 424/93.450
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: Y10S 435/832 Bacillus

Abstract

Compositions containing a lactic acid-producing bacterial strain, e.g., Bacillus coagulans for inhibition of pathogenic bacterial infections. Spores or extracellular products produced by the bacterial strains are also useful as inhibitory agents.

Claims

1. A composition comprising an isolated Bacillus strain, wherein said strain (a) produces lactic acid, (b) has an optimal growth temperature of in the range of 20-44°

C., and (c) grows in a pH range of 2-5.

2. The composition of claim 1, wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90°

C.

3. The composition of claim 1, wherein said strain is selected from the group consisting of Bacillus coagulaus, Bacillus stereothermophilus, Bacillus thermoacidurans, Lactobacillus sporogenes, Bacillus smithii, Bacillus dextrolacticus, Lactobacillus cereale, and Bacillus recemilacticus.

4. The composition of claim 1, wherein said strain is Bacillus coagulans.

5. The composition of claim 1, wherein said strain is selected from the group consisting of Bacillus coagulans GBI-1, Bacillus coagulans GBI-20, Bacillus coagulans GBI-30 and Bacillus coagulans GBI-40.

25. A method of inhibiting a pathogenic bacterial infection, comprising contacting an infected site with the composition of claim 1.

6. (canceled)

7. A composition comprising an isolated Bacillus strain, wherein said strain produces lactic acid and has an optimal growth temperature of in the range of 20-25°

C.

8. The composition of claim 7, wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90°

C.

9. The composition of claim 7, wherein said strain is selected from the group consisting of Bacillus coagulans, Bacillus stereothermophilus, Bacillus thermoacidurans, Lactobacillus sporogenes, Bacillus smithii, Bacillus dextrolacticus, Lactobacillus cereale, and Bacillus recemilacticus.

10. The composition of claim 7, wherein said strain is Bacillus coagulans.

11. The composition of claim 7, wherein said strain is Bacillus coagulans GBI-20.

12. (canceled)

13. A composition comprising an isolated Bacillus strain, wherein said strain produces lactic acid and has an optimal growth temperature of in the range of 25-35°

C.

14. The composition of claim 13, wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90°

C.

15. The composition of claim 13, wherein said strain is selected from the group consisting of Bacillus coagulans, Bacillus stereothermophilus, Bacillus thermoacidurans, Lactobacillus sporogenes, Bacillus smithii, Bacillus dextrolacticus, Lactobacillus cereale, and Bacillus recemilacticus.

16. The composition of claim 13, wherein said strain is Bacillus coagulans.

17-18. -18. (canceled)

19. A composition comprising an isolated Bacillus strain, wherein said strain produces lactic acid and has an optimal growth temperature of in the range of 35-40°

C.

20. The composition of claim 19, wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90°

C.

21. The composition of claim 19, wherein said strain is selected from the group consisting of Bacillus coagulans, Bacillus stereothermophilus, Bacillus thermoacidurans, Lactobacillus sporogenes, Bacillus smithii, Bacillus dextrolacticus, Lactobacillus cereale, and Bacillus recemilacticus.

22. The composition of claim 19, wherein said strain is Bacillus coagulans.

24. An extracellular product derived from the composition of claim 19.

23. (canceled)

26. A method of inhibiting a pathogenic bacterial infection, comprising contacting an infected site with a Bacillus coagulans composition.

27-35. -35. (canceled)